Navigation Links
Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress
Date:8/25/2009

RIDGEFIELD, Conn., Aug. 25 /PRNewswire/ -- Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran)(1) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).(1)

Atrial fibrillation affects approximately 2.3 million Americans(2) and can increase the risk of stroke five-fold.(3) Top-line findings from the 18,113 patient RE-LY study(1) will be featured in an ESC press briefing on Sunday, Aug. 30 at 8:00 a.m. CEST, with the full results presented in a "Hot-Line" session at 11:00 a.m. CEST. The study will also be simultaneously published in a leading peer-reviewed medical journal.

Dabigatran etexilate is an investigational oral anticoagulant in Phase III development for stroke prevention in AF(1) and several other therapeutic areas, including prevention of atherothrombotic events in patients with acute coronary syndrome,(4) as well as primary prevention, (5),(6),(7) secondary prevention(8) and treatment of venous thromboembolism.(9) Dabigatran etexilate is not yet approved by the U.S. Food and Drug Administration.

In addition to the primary findings, a RE-LY sub-analysis of treatment naive patients will also be presented during a "Clinical Trial Update" session on Wednesday, Sept. 2 at 8:00 a.m. CEST.

About RE-LY: The largest AF outcomes trial to date

RE-LY was a global, Phase III, randomized trial of 18,113 patients(1) enrolled in more than 900 centers in 44 countries,(1) investigating whether dabigatran etexilate (two blinded doses) was as effective as well-con
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. CTMM Becomes One of the Worlds Largest Public-Private Partnerships in Translational Medical Research
2. PSA Screening Cuts Deaths by 20%, Says Worlds Largest Prostate Cancer Study
3. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
4. Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series
5. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
6. The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications
7. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
8. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
9. Universite de Montreal Researchers Simulate Worlds Largest Heart Model Using SGI Technology
10. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
11. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... WASHINGTON , Feb. 27, 2015  Following ... Means Committee that moved H.R. 284, the Medicare ... the American Association for Homecare (AAHomecare) released a ... quick action to pass the legislation. ... in the House Ways and Means Committee is ...
(Date:2/27/2015)... YORK , Feb. 27, 2015 Securities ... the board of Salix Pharmaceuticals, Ltd. (NASDAQ: ... $158.00 per share. Concerned SLXP investors are encouraged to ... The investigation focuses upon the shareholder ... agreement, Salix shareholders would receive only $158.00 per share ...
(Date:2/27/2015)... HOUSTON, TX , Feb. 27, 2015 ... EPI) and Bloom Burton & Co. Ltd. ("Bloom Burton") ... lock-up (the "Lock-Up") 2,353,130 common shares of the Company ... subject to the Lock-Up. Of the Common Shares released ... immediately upon release from the Lock-Up while the remainder ...
Breaking Medicine Technology:Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 2ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 3ESSA Pharma and Bloom Burton announce additional release of shares from voluntary lock-up agreement 4
... Sandata Technologies, LLC, a leading national provider of ... announced that on November 16, 2010, the US Patent ... "Time and/or Attendance System Using Synchronized Code," an innovative ... healthcare fraud and abuse.  The Fixed Location Tracker or ...
... Inc. (Nasdaq: BNVI ) announced today that it ... year 2010 ended September 30, 2010 on Thursday, November 11, ... to review the financial results on Thursday, November 11, 2010 ... the call by dialing (877) 317-6789 or (412) 317-6789, or ...
Cached Medicine Technology:Sandata Technologies Launches Enhanced Location Monitoring 2Sandata Technologies Launches Enhanced Location Monitoring 3
(Date:2/28/2015)... 28, 2015 In recent years Medical Marijuana ... practicing physicians as a way for them to expand their ... Cannabis as medicine. Since the FDA still lists Cannabis as ... available to licensed physicians that can help guide them ... Deborah Malka in Santa Cruz, CA is a leader ...
(Date:2/28/2015)... Portland, OR (PRWEB) February 28, 2015 ... Duncan Fletcher of Game Change ... and Shannon Leinert about the benefits of athlete development ... underscores some of the unique challenges that athletes face ... on-field and future success. , Fletcher became involved in ...
(Date:2/28/2015)... 2015 With their commitment to achieving ... an additional exercise to their already robust library of ... most commonly known as, is often performed on a ... executed in a relatively safe manner and can be ... The full description of “Rope Pulls” is located in ...
(Date:2/28/2015)... 28, 2015 The Classic Denture ... a new special. Throughout all of March patients ... , This service can help overall mouth ... pain. Patients may notice certain symptoms that suggest the ... These symptoms include: , 1.    Pain, clicking, and popping in ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate tax ... business consulting services in addition to a variety of ... succession planning. Company finances are a complicated matter that ... of this, complex Canadian tax laws can make it ... result, Mew and Company works to advise their clients ...
Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2
... BELLEVUE, Wash., Sept. 11 The Citizens,Committee for the ... with,Oklahoma Sen. Tom Coburn that there is a serious ... Suicide Prevention Act -- that could,ultimately prevent military veterans ... defend., The problem, as pointed out by Sen. ...
... Thanks to a $1.6 million grant from the Welch ... launching a new initiative to develop innovative computational and ... drugs and molecular tools for biomedical science. , The ... Gulf Coast Consortium for Chemical Genomics (GCC CG) to ...
... with the breast cancer susceptibility gene BRCA1 often remove ... they believe fuels cancer growth. Yet they also know ... ovarian cancer that might develop. That paradox has led ... involved in cancer development and whether removal of ovaries ...
... Inc. (Pink Sheets: MSITF) wishes to announce that it has,completed ... Hepatitis C,test kit in Europe. Completion of this testing will ... EU approval would allow the Company to expand its ... It is anticipated that,when EU approval is received that it ...
... Sept. 11 Responding to a lawsuit by ... national medical,licensing examination, the National Board of Medical ... the needs of breastfeeding mothers as well as,other ... first priority for this test, accepted as evidence ...
... treatment, reseachers say , TUESDAY, Sept. 11 (HealthDay News) ... believe they may have found the disease,s genetic on/off ... to the development of better treatments, the team said. ... mouse model for schizophrenia by inserting the mutant Disrupted-In-Schizophrenia ...
Cached Medicine News:Health News:CCRKBA Backs Sen. Coburn's Opposition to Tenets of H.R. 327 2Health News:Welch Foundation gives $1.6 million for drug discovery research 2Health News:Welch Foundation gives $1.6 million for drug discovery research 3Health News:New clues to breast cancer development in high-risk women 2Health News:New clues to breast cancer development in high-risk women 3Health News:New clues to breast cancer development in high-risk women 4Health News:Medical Services International Inc. Completes Testing for European Union (EU) Application 2Health News:Public Health and Need for Consistent Standards Preclude Exception for Breastfeeding Mother in National Medical Licensing Test 2Health News:Schizophrenia Gene May Have On/Off Switch 2
... suction kits include a Tri-Flo® ... basin and one or two ... without inner wallet. Infant and ... or 10 Fr catheters feature ...
Kit includes whistle tip catheter with two eyes and control vent, 2 vinyl gloves, and pop-up solution container in peel- open package....
Rubber bronchial catheter with thumb valve, one eye, coude whistle tip, with pop-up solution container, two vinyl gloves in peel-open package....
Gentle-Flo® Standard Connector., ,Indications For Usage: ,Removal of secretions from respiratory tract....
Medicine Products: